Funded Projects › FP7
SYSKID · Systems biology towards novel chronic kidney disease diagnosis and treatment
Chronic kidney disease (CKD) affects up to 10% of the population. Besides eventual progression towards end stage renal disease CKD impacts the patient’s quality of life by causing serious comorbidities including cardiovascular complications and bone metabolism disorders. On the everyday clinical level early stage diagnosis and tailored treatment of CKD are still inadequate. In addition, CKD seems not to have reached its appropriate emplacement in an epidemiological and healthcare perspective yet, and the pathophysiology of the disease on a molecular and cellular level is not well enough understood. Our sysKID consortium was installed for precisely addressing these issues: To unravel the molecular and cellular mechanisms of chronic kidney disease development, combine this information with clinical risk factors, and on this basis delineate chronic kidney disease biomarkers. These markers will allow us to perform preclinical studies of novel therapy approaches for halting disease progression, and will provide us with the materials for development and clinical evaluation of tools for early stage diagnosis as well as prognosis and treatment monitoring. sysKID assures a successful implementation of these goals by a truly international consortium of 27 leading research groups. We combine clinical know how, provide access to a huge chronic kidney disease sample and clinical data pool, and build a Systems Biology framework for chronic kidney disease by integrating molecular and cellular biology, computational biology, statistics and epidemiology. Our expert group is further complemented by a high level advisory board covering science, product development, and the patient’s perspective. sysKID implementation is structured for completing pre-clinical Proof of Concept studies of novel chronic kidney disease therapy regimes, and further for completing clinical evaluation of an epidemiological screening tool as well as of early stage chronic kidney disease diagnostic kits.
Consortium · 29 organisations
EMERGENTEC BIODEVELOPMENT GMBH
AT · €816,380
NOVO NORDISK INVEST 4 A/S
DK · €336,672
MEDIZINISCHE UNIVERSITAET WIEN
AT · €965,360
INSTITUT CATALA DE LA SALUT
ES · €457,052
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
IE · €485,500
UNIVERSITAETSKLINIKUM AACHEN
DE · €125,640
WEIZMANN INSTITUTE OF SCIENCE
IL · €506,716
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
IT · €457,160
ACADEMISCH ZIEKENHUIS GRONINGEN
NL · €620,120
CELERA CORPORATION
US · €258,000
UNIVERSITE VICTOR SEGALEN BORDEAUX II
FR
MEDIZINISCHE UNIVERSITAT INNSBRUCK
AT · €1,526,360
CONSIGLIO NAZIONALE DELLE RICERCHE
IT · €186,614
UNIVERSITE DE BORDEAUX
FR · €261,160
UNIVERSIDAD DE CORDOBA
ES · €226,800
AMGEN (EUROPE) GMBH
CH · €31,200
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
DE · €924,920
SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH
PL · €166,240
BIOGAZELLE NV
BE · €417,060
SEMMELWEIS EGYETEM
HU · €166,240
UNIVERSITY OF GLASGOW
UK · €166,240
UNIVERSITATSKLINIKUM ERLANGEN
DE · €336,160
ProScience Communications - die Agentur fur Wissenschaftskommunikation GmbH
DE · €114,000
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
NL · €385,160
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
ES
MOSAIQUES DIAGNOSTICS GMBH
DE · €662,140
THE ANTIBODY LAB GMBH
AT · €446,800
BIOCRATES LIFE SCIENCES AG
AT · €288,120
UNIVERSITAT DES SAARLANDES
DE · €455,720
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.